PHA Canada is Pleased to Announce the 2018 Paroian Family PH Research Scholarship Award Recipient

PHA Canada is Pleased to Announce the 2018 Paroian Family PH Research Scholarship Award Recipient

02.19.2019

The Pulmonary Hypertension Association of Canada (PHA Canada) is pleased to announce that the third recipient of the Paroian Family PH Research Scholarship is Dr. François Potus, a Postdoctoral Fellow at Queen’s University’s Department of Medicine in Kingston (ON).

Scholarships of up to $10,000 are offered by PHA Canada to promote and support PH researchers in Canada. The Paroian Family PH Research Scholarship is named to recognize the incredible contribution of the Paroian Family to the Canadian PH community.

FP-photo.jpegDr. François Potus
Queen’s University, Department of Medicine (Kingston, ON)

Under the supervision of:
Dr. Stephen L. Archer, Head of the Department of Medicine, Queen’s University, Faculty of Health Science (Kingston, ON). 

Dr. François Potus is currently a Postdoctoral Fellow in the Department of Medicine at Queen's University (Kingston, ON). He obtained a Master’s Degree with distinction in Molecular Biology and Genetics at the Université Claude Bernard Lyon 1, in France, and completed his PhD in Molecular and Cellular Biology at Laval University in Québec, Canada. Dr. Potus is a Physiologist and Molecular Biologist with expertise in cardiovascular research and genetics. His main work currently focuses on the epigenetic regulation of gene expression in pulmonary arterial hypertension (PAH). More specifically, he is interested in exploring the role that DNA methylation plays in pathological regulation of gene expression in pulmonary arterial hypertension.

Dr. Potus’s Project: Linking inflammation and the progression of pulmonary arterial hypertension
Research team: Dr. François Potus, Queen’s University (Kingston, ON), Dr. Archer’s Lab

Pulmonary arterial hypertension (PAH) is a severe lung disease in which blood circulation in the lungs gets blocked. This results in a combination of increased pressure, abnormal cell growth, and increased inflammation. We have identified special modifications to DNA (“epigenetic changes”) that alter the way genes are expressed in PAH lungs.

This study will investigate the role of a critical regulator of this epigenetic mechanism—called ten-eleven-translocase (TET2)—in the development of PAH. We will determine if artificial modulation of TET2 worsens or improves disease outcomes in an animal model of PAH. We will then investigate lung inflammation, cell proliferation, and TET2 expression to understand how this factor contributes to the disease. Finally, using an animal model of PAH, we will investigate which section(s) of DNA are targeted by epigenetic changes and determine the link between TET2, the identified genes, inflammation, and cell proliferation.

This project aims to increase basic knowledge of PAH etiology and investigate TET2 modulation as a potential cure for PAH.

Recent News

Subscribe

Get the latest on PH treatments, community events and more when you subscribe to our newsletter

ImagineCan_Accreditation_Trustmark_ENGFR_WHT-FNL_white.png